December 16, 2022 - Non-regulatory SynAct Pharma initiates dosing in the RESOLVE study in DMARD-IR RA
December 12, 2022 - Regulatory SynAct Pharma to make strategic acquisition of Swiss biotech company TXP Pharma
December 12, 2022 - Regulatory SynAct Pharma carries out a directed share issue of SEK 80 million in connection with the acquisition of TXP Pharma
November 1, 2022 - Non-regulatory SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA
September 27, 2022 - Non-regulatory SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA
August 16, 2022 - Non-regulatory Resomelagon proposed international nonproprietary name (INN) for AP1189
July 21, 2022 - Non-regulatory SynAct Pharma improves the design of the ongoing Phase 2a study in iMN
May 20, 2022 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022
May 12, 2022 - Regulatory Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB
April 1, 2022 - Non-regulatory SynAct publishes prospectus in connection with a fully guaranteed rights issue
March 28, 2022 - Regulatory Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB
March 28, 2022 - Regulatory SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million
March 9, 2022 - Regulatory The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB
